Potassium%25252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride is an electrolyte replacement used to treat or prevent hypokalemia. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia in patients receiving diuretics or other medications that cause potassium loss. ## Adult Dosing * **Treatment of Hypokalemia:** Typically 20-60 mEq per day, administered in 2-4 divided doses. Doses up to 100 mEq per day may be necessary in severe cases. * **Prevention of Hypokalemia:** Typically 20-40 mEq per day. * **Maximum dose:** Generally not to exceed 100 mEq per day. Specific maximums may vary based on severity and clinical judgment. * **Oral formulations:** Available as tablets, capsules, and liquid. Dilute liquid formulations significantly before administration to minimize gastrointestinal irritation. * **Intravenous (IV) formulations:** Administer with extreme caution. IV potassium infusion rates and concentrations must be carefully controlled to prevent fatal hyperkalemia. Standard protocols for IV potassium administration are critical and often determined by local hospital policy. Typical infusion rates are 10-20 mEq/hour, with a maximum concentration of 40 mEq/L (in most peripheral lines) and 80 mEq/L (in central lines), and a maximum rate of 20 mEq/hour. Higher rates (up to 40 mEq/hour) or concentrations may be used in emergent, life-threatening hypokalemia under close cardiac monitoring, typically in an ICU setting. ## Pediatric Dosing * **General maintenance requirements:** 1-2 mEq/kg/day. * **Treatment of hypokalemia:** 2-4 mEq/kg/day divided into 2-4 doses. * **Maximum dose:** Generally not to exceed 10-20 mEq/day. * **IV administration:** Must be highly diluted and infused slowly. Concentrations typically should not exceed 40 mEq/L. Rates are usually limited to 0.5-1 mEq/kg/hour. Close monitoring is essential. Local pediatric protocols are essential for IV potassium administration. ## Dose Adjustments * **Renal impairment:** Dose should be reduced. Monitor potassium levels closely. Contraindicated in severe renal impairment. * **Adrenal insufficiency:** Requires careful monitoring and potential dose adjustment. ## Contraindications * Hyperkalemia (serum potassium > 5.0 mEq/L). * Conditions that may predispose to hyperkalemia, such as untreated Addison's disease, acute dehydration, extensive tissue injury, or certain renal impairments. * Certain medications that cause potassium retention (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics) may require dose adjustments or contraindicate concomitant use depending on renal function and potassium levels. ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea. * **Serious:** Hyperkalemia (potentially fatal), cardiac arrhythmias, cardiac arrest, ECG changes, muscle weakness, paralysis. Esophageal or gastric ulceration/perforation (especially with slow-release formulations or inadequate dilution). ## Key Drug Interactions * **ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), Trimethoprim, Cyclosporine, Tacrolimus:** Increased risk of hyperkalemia. * **Potassium-containing salt substitutes:** Can significantly increase potassium intake and risk of hyperkalemia. * **Diuretics (other than potassium-sparing):** May cause potassium loss, necessitating potassium supplementation. * **Beta-blockers:** May increase serum potassium levels. * **Digoxin:** Hyperkalemia can increase the toxicity of digoxin. Hypokalemia can increase the toxicity of digoxin. ## Monitoring * **Serum potassium levels:** Frequently, especially during initiation, dose changes, or in patients with renal impairment or risk factors for hyperkalemia. * **Renal function:** Monitor BUN and creatinine. * **ECG:** Particularly important during IV administration or if hyperkalemia is suspected. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium supplements can be irritating to the gastrointestinal tract. Advise patients to take with meals and plenty of fluid, or to dilute liquid preparations well. * Slow-release formulations may be better tolerated but carry a risk of intestinal obstruction or perforation, particularly in patients with decreased gastrointestinal motility. * IV potassium administration is a high-risk procedure requiring meticulous attention to detail regarding concentration, rate of infusion, and patient monitoring. Never administer IV potassium undiluted or as a bolus. * Consider the total potassium load from all sources, including diet, salt substitutes, and other medications. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for definitive patient care decisions. Dosing and administration can vary significantly based on individual patient factors and clinical circumstances.